Addex Therapeutics, a company involved in allosteric modulation-based drug discovery and development, has granted an option to license its metabotropic glutamate receptor subtype 3 (mGlu3 receptor) program to Pierre Fabre Pharmaceuticals, a laboratory with a track-record in discovering, developing and marketing products in the field of central nervous system (CNS). “This agreement confirms our strong and continued interest in the CNS field to develop therapies addressing critical global...